MediciNova director Jeff Himawan to not stand for re-election due to health reasons

MEDICINOVA INC

Dr. Jeff Himawan notified Board he will not stand for re-election as Class I director at 2023 annual meeting.
Decision solely due to personal health reasons; no disagreement with Company operations, policies, or practices.
His term ends at the Annual Meeting; seat will remain vacant until filled per Company Bylaws.
Company thanks Dr. Himawan for his leadership and service.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeff Himawan

Director

MNOV · MEDICINOVA INC

Filed: April 26, 2023, 7:59 PM ET

On April 20, 2023, Jeff Himawan, Ph.D., a member of the Board of Directors (the “Board”) of MediciNova, Inc. (the “Company”) notified the Board that he will not stand for re-election as a Class I director of the Company at the Company’s 2023 annual meeting of stockholders (the “Annual Meeting”) due solely to a personal decision related to health reasons.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeff Himawan departed as Director at MEDICINOVA INC.

Action: will not stand for re-election
Role: Director

Exact text from the filing

On April 20, 2023, Jeff Himawan, Ph.D., a member of the Board of Directors (the “Board”) of MediciNova, Inc. (the “Company”) notified the Board that he will not stand for re-election as a Class I director of the Company at the Company’s 2023 annual meeting of stockholders (the “Annual Meeting”) due solely to a personal decision related to health reasons.

View on SEC.gov

MEDICINOVA INC filing history →

Source: SEC EDGAR

accession 0001193125-23-118572

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.